MaxCyte, Inc.
9713 Key West Ave., Suite 400
Rockville
Maryland
20850
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
216 articles about MaxCyte, Inc.
-
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
7/10/2023
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.
-
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
7/6/2023
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.
-
MaxCyte to Participate in Upcoming June 2023 Investor Conferences
6/1/2023
MaxCyte, Inc. announced Company management will participate at the following investor conferences:
-
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
5/10/2023
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance.
-
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
5/4/2023
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.
-
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
4/12/2023
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the first quarter 2023 after the U.S. market close on Wednesday, May 10th, 2023.
-
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
3/27/2023
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) today announced Douglas J. Swirsky has been appointed as the Company’s Chief Financial Officer, effective immediately.
-
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
3/15/2023
MaxCyte, Inc. announced its fourth quarter and full year ended December 31, 2022, financial results and provided initial 2023 revenue guidance.
-
MaxCyte Establishcientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
3/8/2023
MaxCyte, Inc. today announced the formation of its new Scientific Advisory Board (SAB) that will reflect the cutting edge of research in molecular design and cell engineering.
-
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
3/6/2023
MaxCyte, Inc. today announced preliminary revenue results for the fourth quarter and full year 2022 and provided initial 2023 revenue guidance.
-
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
2/1/2023
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023.
-
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
1/3/2023
MaxCyte, Inc. announced the signing of a strategic platform license with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor -NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.
-
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
12/5/2022
MaxCyte, Inc. and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, announced the signing of a strategic platform license.
-
MaxCyte Reports Third Quarter 2022 Financial Results
11/9/2022
MaxCyte, Inc. announced financial results for the third quarter ended September 30, 2022.
-
MaxCyte to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
MaxCyte, Inc. announced Company management will participate in the following investor conferences:
-
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
10/12/2022
MaxCyte, Inc. today announced that it will release financial results for the third quarter of 2022 after the U.S. market close on Wednesday, November 9th , 2022.
-
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
9/28/2022
MaxCyte, Inc. today announces the signing of a strategic platform license (SPL) with Vertex Pharmaceuticals Incorporated, a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
-
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
9/21/2022
MaxCyte, Inc. announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor.
-
MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
9/7/2022
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.
-
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
8/10/2022
MaxCyte, Inc. announced financial results for the second quarter and six months ended June 30, 2022.